Fulgent Genetics, Inc. (FLGT) Stock Price & Analysis
Fulgent Genetics, Inc. (FLGT) rose 0.41% to USD 19.73 as of September 8, 2026 at 05:01 UTC, according to Nexqual real-time market data.
FLGT last closed at USD 19.73; the session ranged USD 19.38–19.86 on volume of 224,999 shares. Market capitalization is —, with a 52-week range of USD 13.46–31.04 (NGM). Source: Nexqual, September 8, 2026 at 05:01 UTC.
Key Statistics (as of September 8, 2026 at 05:01 UTC)
| Price | USD 19.73 |
|---|---|
| Change | ▲ 0.41% (up) |
| Previous Close | USD 19.73 |
| Open | USD 19.73 |
| Day Range | USD 19.38 – 19.86 |
| 52-Week Range | USD 13.46 – 31.04 |
| Volume | 224,999 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (FLGT)
Nexqual's technical model rates FLGT "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:01 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 51.29 (neutral) |
| vs SMA50 | Above (USD 19.69) |
| MACD | 0.15 (positive) |
From Fulgent Genetics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Picture tests help individuals identify important health markers to empower their personal health journey. 1   Our Laboratory Services Technology Platform Our proprietary technology platform for our laboratory services business includes proprietary gene probes, data suppression and comparison algorithms, AI learning software, and proprietary laboratory information management systems.
- We seek to protect our proprietary technology and processes, and obtain and maintain ownership of certain technologies, in part, through non-disclosure and intellectual property assignment agreements with our employees, consultants, and commercial partners.
- We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems.
- This acquisition enables us to secure full ownership of the patents we previously licensed from ANP to develop, strengthen, and maintain our proprietary position in the fields targeted by our product candidates, including FID-007 and FID-022, which are currently in clinical studies.
Partnerships
- Previously, in June 2017, we entered into an exclusive license agreement with ANP Technologies, Inc., or ANP, as amended on December 28, 2017, and May 1, 2024.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| APPN | Appian Corporation | USD 38.37 | ▼ 3.81% |
| FVRR | Fiverr International Ltd. | USD 9.25 | ▼ 1.91% |
| MGNI | Magnite, Inc. | USD 24.14 | ▼ 2.97% |
| KNSL | Kinsale Capital Group, Inc. | USD 373.17 | ▼ 0.96% |
| WD | Walker & Dunlop, Inc | USD 42.61 | ▲ 6.34% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:01 UTC. This page is informational and not investment advice.